DYN Stock — Dyne Therapeutics, Inc.: Metrics

Market overview

2 metrics

Share price

$25.10

Market cap

$4.66B

Price action

19 metrics

Price change (1W)

-4.7%

Price change (30D)

-0.6%

Price change (3M)

+45.6%

Price change (6M)

+71.9%

Price change (YTD)

+28.3%

Price change (1Y)

+86.1%

Trailing year

Price change (5Y)

+48.4%

52-week high

$26.78

52-week low

$12.37

Change from 52-week high

-6.3%

Change from 52-week low

+102.9%

Annualized volatility

77.1%

Beta

2.0

RSI (14D)

47.1

Price vs SMA 50

+2.5%

Price vs SMA 200

+26.5%

Avg volume (3M)

2.22M

Relative volume

0.7

Average dollar volume

$51.18M

Company

3 metrics

Sector

Healthcare

Industry

Biotechnology

Shares outstanding

186.75M

Valuation

12 metrics

P / E (TTM)

—

Trailing earnings

PEG ratio

—

EV / revenue

—

EV / EBITDA

—

EV / EBIT

—

P / sales

—

P / book

6.6

reciprocal yield 15.1%

FCF yield

-10.3%

TTM · current market cap

Buyback yield

—

P / FCF

—

P / operating cash flow

—

Earnings yield

-1.6%

Historical valuation

8 metrics

P / E historical average (3Y)

—

P / E historical average (5Y)

—

EV / revenue historical average (3Y)

—

EV / revenue historical average (5Y)

—

EV / EBIT historical average (3Y)

—

EV / EBIT historical average (5Y)

—

EV / EBITDA historical average (3Y)

—

EV / EBITDA historical average (5Y)

—

Dividends & buybacks

7 metrics

Dividend yield

—

Trailing 12 months

Payout ratio

—

Shareholder yield

—

Dividend / share (TTM)

—

Dividend growth YoY

—

Dividend growth streak

—

Last ex-dividend

—

Earnings calendar

2 metrics

Next earnings

—

Last earnings

2024-09-03

Profitability

9 metrics

Gross margin

—

Operating margin

—

Trailing 12 months

Net margin

—

Gross profit (TTM)

—

Operating profit (TTM)

−$536.96M

Net income (TTM)

−$73.19M

Trailing 12 months

Diluted EPS (TTM)

$-3.26

FCF margin

—

Effective tax rate

—

Per share

11 metrics

Revenue per diluted share (TTM)

—

Gross profit per diluted share (TTM)

—

Operating profit per diluted share (TTM)

—

EBITDA per diluted share (TTM)

—

Net income per diluted share (TTM)

—

Operating cash flow per diluted share (TTM)

—

Free cash flow per diluted share (TTM)

—

Capital expenditures per diluted share (TTM)

—

R&D per diluted share (TTM)

—

Stock compensation per diluted share (TTM)

—

Book value per share

$5.24

Growth

11 metrics

Revenue growth YoY

—

Year over year

Net income growth YoY

—

Revenue (TTM)

—

Trailing 12 months

EPS growth YoY

—

Shares change YoY

+0.9%

Year over year · more shares

Revenue CAGR (3Y)

—

Revenue CAGR (5Y)

—

EPS CAGR (3Y)

—

EPS CAGR (5Y)

—

FCF CAGR (3Y)

—

FCF CAGR (5Y)

—

Quality

14 metrics

Return on equity

-10.4%

Return on assets

-7.4%

Debt / equity

0.3

Current ratio

12.0

EBITDA (TTM)

—

Free cash flow (TTM)

−$480.43M

Quick ratio

12.0

Interest coverage

—

Net debt / EBITDA

—

Return on invested capital

—

Trailing 12 months

Net cash

$476.79M

Latest balance sheet

Cash & equivalents

$676.11M

Total assets

$994.01M

Total debt

$199.33M

Cash flow & spend

7 metrics

Operating cash flow (TTM)

−$477.82M

Capital expenditures (TTM)

$2.61M

R&D (TTM)

$445.71M

SG&A (TTM)

—

Stock compensation (TTM)

$50.37M

R&D / revenue

—

Stock compensation / revenue

—

Ownership (13F)

3 metrics

13F filers

247

13F filer change QoQ

+17

Institutional ownership

102.2%

Short interest

3 metrics

Short interest

11.5%

Latest settlement · 11.0 days to cover

Days to cover

11.0d

Short-squeeze score

72 / 100

Insider activity

2 metrics

Net insider buying (90D)

−$113.54M

Insider-sentiment score

65 / 100

Risk flags

1 metrics

Going concern

—

DYN · Dyne Therapeutics, Inc.

DYN metrics

Market overview

Price action

Company

Valuation

Historical valuation

Dividends & buybacks

Earnings calendar

Profitability

Growth

Quality

Cash flow & spend

Ownership (13F)

Short interest

Insider activity

Risk flags

No metrics match that search